Impact of Chemotherapy Dose Intensity and Neutropenia on Early Breast Cancer Outcomes

Overview

This retrospective cohort study found that reduced chemotherapy relative dose intensity (RDI) below 85% is associated with worse survival primarily in early breast cancer patients without treatment-related neutropenia (rCIN). Patients experiencing rCIN did not show significant survival differences despite lower chemotherapy intensity, suggesting rCIN modifies the prognostic impact of dose reductions.

Background

Maintaining optimal chemotherapy dose intensity is critical in early breast cancer to maximize treatment efficacy and improve survival. A relative dose intensity (RDI) of at least 85% is generally recommended, as lower doses have been linked to poorer outcomes. Chemotherapy-induced neutropenia (CIN) often leads to dose reductions or delays, potentially compromising RDI, but emerging evidence suggests CIN may also indicate adequate drug exposure and chemosensitivity. This study explores how relevant chemotherapy-induced neutropenia (rCIN) influences the prognostic effect of reduced RDI.

Data Highlights

The study analyzed early breast cancer patients treated with anthracycline/cyclophosphamide followed by taxanes. RDI was calculated as the ratio of delivered to standard dose intensity, with <85% considered reduced. Relevant chemotherapy-induced neutropenia (rCIN) was defined by treatment modifications due to neutropenia. Survival outcomes (overall survival and disease-free survival) were assessed using Kaplan–Meier and Cox proportional hazards models over a median follow-up of approximately 4.1 years, truncated at 5 years for Kaplan–Meier analyses.

Key Findings

• Reduced RDI (<85%) was linked to inferior survival mainly in patients without treatment-relevant chemotherapy-induced neutropenia (rCIN).
• Patients experiencing rCIN showed no significant differences in overall or disease-free survival despite lower chemotherapy dose intensity.
• The presence of rCIN may serve as a pharmacodynamic marker of adequate chemotherapy exposure and chemosensitivity.
• Infectious complications related to chemotherapy did not significantly alter the association between RDI and survival outcomes.
• Multivariable Cox models retained rCIN, RDI <85%, and their interaction as key predictors, confirming the modifying effect of rCIN on the prognostic impact of dose intensity.

Clinical Implications

Clinicians should consider that reduced chemotherapy dose intensity may not uniformly predict poorer outcomes in early breast cancer patients, particularly those who develop treatment-related neutropenia. Monitoring for rCIN could help identify patients in whom dose reductions are less detrimental, potentially guiding individualized chemotherapy dosing strategies. This insight supports a nuanced approach to managing chemotherapy toxicity without compromising efficacy.

Conclusion

The negative prognostic impact of diminished chemotherapy dose intensity in early breast cancer is attenuated in patients experiencing treatment-related neutropenia. Recognizing rCIN as a marker of adequate drug exposure may refine risk stratification and treatment personalization.

References

1. University Hospital Tübingen Study 2014-2021 -- Retrospective Cohort Analysis on Chemotherapy Dose Intensity and Neutropenia